跳至主要内容
临床试验/NCT04281147
NCT04281147已完成不适用

Real World Evaluation of Access-driven Canadian Treatment Sequences in Progressive Prostate Cancer

Bayer1 个研究点 分布在 1 个国家目标入组 4,301 人开始时间: 2020年2月24日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Bayer
入组人数
4,301
试验地点
1
主要终点
Overall survival

研究概览

简要总结

Study to gather information about the optimal placement of Ra-223 in the order of different treatments in terms of the effect on patients and in terms of the use of healthcare services for the treatment of Canadian patients with prostate gland cancer which spread to other parts of the body. In order to collect this information real world data from prostate gland cancer patients from four Canadian administrative databases will be analyzed.

Data collected from patients treated with their 2nd line of life-prolonging therapy for Non-Metastatic Castration Resistant Prostate Cancer (mCRPC) initiated from 01 Jan 2012 to 31 Dec 2017. For patients included in the study, all available data from the beginning for their record until death, lost to follow-up or database cut-off will be included. The index date is the date of initiation of the 2nd line life-prolonging therapy for mCRPC.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

性别
Male
接受健康志愿者

入选标准

  • Use of at least 2 lines of life-prolonging mCRPC therapy
  • The 2nd line of life-prolonging therapy was initiated between 01-Jan-2012 to 31-Dec-2017

排除标准

  • No formal exclusion criteria will be applied in order to capture real world use of Ra-223

研究组 & 干预措施

Early Ra-223 (2nd line)

Patients received Ra-223 in 2nd line

干预措施: Radium-223 dichloride (Xofigo, BAY88-8223) (Drug)

Late Ra-223 (3rd or later lines)

Patients received Ra-223 in 3rd or later lines

干预措施: Radium-223 dichloride (Xofigo, BAY88-8223) (Drug)

结局指标

主要结局

Overall survival

时间窗: Retrospective analysis from 01-Jan-2012 to 31-Dec-2017

The length of time from the date of initiation of 2nd line life-prolonging therapy to death due to any cause

次要结局

  • Time to first hospitalization(Retrospective analysis from 01-Jan-2012 to 31-Dec-2017)
  • Event-free survival (EFS)(Retrospective analysis from 01-Jan-2012 to 31-Dec-2017)
  • Time to External Beam Radiation Therapy (EBRT)(Retrospective analysis from 01-Jan-2012 to 31-Dec-2017)
  • Total incidence of EBRT(Retrospective analysis from 01-Jan-2012 to 31-Dec-2017)
  • Number of overnight hospital stays(Retrospective analysis from 01-Jan-2012 to 31-Dec-2017)
  • Average length of hospital stays (number of days)(Retrospective analysis from 01-Jan-2012 to 31-Dec-2017)
  • Time to first Emergency Room (ER) visit(Retrospective analysis from 01-Jan-2012 to 31-Dec-2017)
  • Number of visits to the ER(Retrospective analysis from 01-Jan-2012 to 31-Dec-2017)

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验